Global Staphylococcal Infection Drugs Market
Global Staphylococcal Infection Drugs Market

Staphylococcal Infection Drugs Comprehensive Study by Type (Beta-lactams, Peptides, Quinolones, Others), Application (Hospital, Pharmacy, Others), Treatment (Antibiotics, Wound Drainage, Device Removal), Diagnosis (Physical Exam, Tissue Sample or Nasal Secretions, Imaging Test (Echocardiogram)) Players and Region - Global Market Outlook to 2025

Staphylococcal Infection Drugs Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Nov 2020 Edition 234 Pages 213 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Staphylococcal Infection Drugs Market Scope
Staphylococcus infection is caused by staph or staphylococcus bacteria. Staphylococcus is a group of bacteria (microbe or germ) that can cause a number of infectious diseases in various tissues of the body. There are more than 30 types. A type called Staphylococcus aureus causes most infections. People with diabetes or weakened immunity are particularly prone to developing this infection. Treatment of a staph infection includes antibiotics, wound drainage, and device removal.

The Staphylococcal Infection Drugs market study is segmented by Type (Beta-lactams, Peptides, Quinolones and Others), by Application (Hospital, Pharmacy and Others) and major geographies with country level break-up.

The global Staphylococcal Infection Drugs market is fragmented and rely on strategies such as mergers & acquisitions, product development, geographical expansion, and sourcing strategies to enhance their market share. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Staphylococcal Infection Drugs market throughout the predicted period.

The Medicines Company (United States), Theravance Biopharma (United States), Allergan Plc (Ireland), Bayer AG (Germany), GlaxoSmithKline Plc (United Kingdom), Merck & Co. Inc. (United States), Pfizer Inc (United States) and XBiotech Inc. (United States) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Staphylococcal Infection Drugs market by Type, Application and Region.

On the basis of geography, the market of Staphylococcal Infection Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

In April 2017, XBiotech Inc. announced top-line results from its double-blind, placebo-controlled, phase I-II study evaluating the safety and efficacy of its FDA Fast Tracked true human antibody (514G3) for the treatment of Staphylococcus aureus bloodstream infections.


Market Trend
  • Inventions of new drug classes and vaccines
  • Rise in the Government Funding for Research and Development

Market Drivers
  • Rising Prevalence of Staphylococcal Infections
  • Increasing Skin and Soft Tissue Infections Caused by Staphylococcus

Opportunities
  • Increased Research and Development Activities

Restraints
  • High-Cost AssociatedS with Clinical Trials
  • Lack of Awareness about New Drugs

Challenges
  • Stringent Government Regulation associated with Staphylococcal Infection Drugs


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Staphylococcal Infection Drugs Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Beta-lactams
  • Peptides
  • Quinolones
  • Others
By Application
  • Hospital
  • Pharmacy
  • Others
By Treatment
  • Antibiotics
  • Wound Drainage
  • Device Removal

By Diagnosis
  • Physical Exam
  • Tissue Sample or Nasal Secretions
  • Imaging Test (Echocardiogram)

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Staphylococcal Infections
      • 3.2.2. Increasing Skin and Soft Tissue Infections Caused by Staphylococcus
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Regulation associated with Staphylococcal Infection Drugs
    • 3.4. Market Trends
      • 3.4.1. Inventions of new drug classes and vaccines
      • 3.4.2. Rise in the Government Funding for Research and Development
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Staphylococcal Infection Drugs, by Type, Application, Treatment, Diagnosis and Region (value and price ) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Staphylococcal Infection Drugs (Value)
      • 5.2.1. Global Staphylococcal Infection Drugs by: Type (Value)
        • 5.2.1.1. Beta-lactams
        • 5.2.1.2. Peptides
        • 5.2.1.3. Quinolones
        • 5.2.1.4. Others
      • 5.2.2. Global Staphylococcal Infection Drugs by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Pharmacy
        • 5.2.2.3. Others
      • 5.2.3. Global Staphylococcal Infection Drugs by: Treatment (Value)
        • 5.2.3.1. Antibiotics
        • 5.2.3.2. Wound Drainage
        • 5.2.3.3. Device Removal
      • 5.2.4. Global Staphylococcal Infection Drugs by: Diagnosis (Value)
        • 5.2.4.1. Physical Exam
        • 5.2.4.2. Tissue Sample or Nasal Secretions
        • 5.2.4.3. Imaging Test (Echocardiogram)
      • 5.2.5. Global Staphylococcal Infection Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Staphylococcal Infection Drugs (Price)
      • 5.3.1. Global Staphylococcal Infection Drugs by: Type (Price)
  • 6. Staphylococcal Infection Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. The Medicines Company (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Theravance Biopharma (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Allergan Plc (Ireland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bayer AG (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GlaxoSmithKline Plc (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck & Co. Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer Inc (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. XBiotech Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Staphylococcal Infection Drugs Sale, by Type, Application, Treatment, Diagnosis and Region (value and price ) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Staphylococcal Infection Drugs (Value)
      • 7.2.1. Global Staphylococcal Infection Drugs by: Type (Value)
        • 7.2.1.1. Beta-lactams
        • 7.2.1.2. Peptides
        • 7.2.1.3. Quinolones
        • 7.2.1.4. Others
      • 7.2.2. Global Staphylococcal Infection Drugs by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Pharmacy
        • 7.2.2.3. Others
      • 7.2.3. Global Staphylococcal Infection Drugs by: Treatment (Value)
        • 7.2.3.1. Antibiotics
        • 7.2.3.2. Wound Drainage
        • 7.2.3.3. Device Removal
      • 7.2.4. Global Staphylococcal Infection Drugs by: Diagnosis (Value)
        • 7.2.4.1. Physical Exam
        • 7.2.4.2. Tissue Sample or Nasal Secretions
        • 7.2.4.3. Imaging Test (Echocardiogram)
      • 7.2.5. Global Staphylococcal Infection Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Staphylococcal Infection Drugs (Price)
      • 7.3.1. Global Staphylococcal Infection Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Staphylococcal Infection Drugs: by Type(USD Million)
  • Table 2. Staphylococcal Infection Drugs Beta-lactams , by Region USD Million (2014-2019)
  • Table 3. Staphylococcal Infection Drugs Peptides , by Region USD Million (2014-2019)
  • Table 4. Staphylococcal Infection Drugs Quinolones , by Region USD Million (2014-2019)
  • Table 5. Staphylococcal Infection Drugs Others , by Region USD Million (2014-2019)
  • Table 6. Staphylococcal Infection Drugs: by Application(USD Million)
  • Table 7. Staphylococcal Infection Drugs Hospital , by Region USD Million (2014-2019)
  • Table 8. Staphylococcal Infection Drugs Pharmacy , by Region USD Million (2014-2019)
  • Table 9. Staphylococcal Infection Drugs Others , by Region USD Million (2014-2019)
  • Table 10. Staphylococcal Infection Drugs: by Treatment(USD Million)
  • Table 11. Staphylococcal Infection Drugs Antibiotics , by Region USD Million (2014-2019)
  • Table 12. Staphylococcal Infection Drugs Wound Drainage , by Region USD Million (2014-2019)
  • Table 13. Staphylococcal Infection Drugs Device Removal , by Region USD Million (2014-2019)
  • Table 14. Staphylococcal Infection Drugs: by Diagnosis(USD Million)
  • Table 15. Staphylococcal Infection Drugs Physical Exam , by Region USD Million (2014-2019)
  • Table 16. Staphylococcal Infection Drugs Tissue Sample or Nasal Secretions , by Region USD Million (2014-2019)
  • Table 17. Staphylococcal Infection Drugs Imaging Test (Echocardiogram) , by Region USD Million (2014-2019)
  • Table 18. South America Staphylococcal Infection Drugs, by Country USD Million (2014-2019)
  • Table 19. South America Staphylococcal Infection Drugs, by Type USD Million (2014-2019)
  • Table 20. South America Staphylococcal Infection Drugs, by Application USD Million (2014-2019)
  • Table 21. South America Staphylococcal Infection Drugs, by Treatment USD Million (2014-2019)
  • Table 22. South America Staphylococcal Infection Drugs, by Diagnosis USD Million (2014-2019)
  • Table 23. Brazil Staphylococcal Infection Drugs, by Type USD Million (2014-2019)
  • Table 24. Brazil Staphylococcal Infection Drugs, by Application USD Million (2014-2019)
  • Table 25. Brazil Staphylococcal Infection Drugs, by Treatment USD Million (2014-2019)
  • Table 26. Brazil Staphylococcal Infection Drugs, by Diagnosis USD Million (2014-2019)
  • Table 27. Argentina Staphylococcal Infection Drugs, by Type USD Million (2014-2019)
  • Table 28. Argentina Staphylococcal Infection Drugs, by Application USD Million (2014-2019)
  • Table 29. Argentina Staphylococcal Infection Drugs, by Treatment USD Million (2014-2019)
  • Table 30. Argentina Staphylococcal Infection Drugs, by Diagnosis USD Million (2014-2019)
  • Table 31. Rest of South America Staphylococcal Infection Drugs, by Type USD Million (2014-2019)
  • Table 32. Rest of South America Staphylococcal Infection Drugs, by Application USD Million (2014-2019)
  • Table 33. Rest of South America Staphylococcal Infection Drugs, by Treatment USD Million (2014-2019)
  • Table 34. Rest of South America Staphylococcal Infection Drugs, by Diagnosis USD Million (2014-2019)
  • Table 35. Asia Pacific Staphylococcal Infection Drugs, by Country USD Million (2014-2019)
  • Table 36. Asia Pacific Staphylococcal Infection Drugs, by Type USD Million (2014-2019)
  • Table 37. Asia Pacific Staphylococcal Infection Drugs, by Application USD Million (2014-2019)
  • Table 38. Asia Pacific Staphylococcal Infection Drugs, by Treatment USD Million (2014-2019)
  • Table 39. Asia Pacific Staphylococcal Infection Drugs, by Diagnosis USD Million (2014-2019)
  • Table 40. China Staphylococcal Infection Drugs, by Type USD Million (2014-2019)
  • Table 41. China Staphylococcal Infection Drugs, by Application USD Million (2014-2019)
  • Table 42. China Staphylococcal Infection Drugs, by Treatment USD Million (2014-2019)
  • Table 43. China Staphylococcal Infection Drugs, by Diagnosis USD Million (2014-2019)
  • Table 44. Japan Staphylococcal Infection Drugs, by Type USD Million (2014-2019)
  • Table 45. Japan Staphylococcal Infection Drugs, by Application USD Million (2014-2019)
  • Table 46. Japan Staphylococcal Infection Drugs, by Treatment USD Million (2014-2019)
  • Table 47. Japan Staphylococcal Infection Drugs, by Diagnosis USD Million (2014-2019)
  • Table 48. India Staphylococcal Infection Drugs, by Type USD Million (2014-2019)
  • Table 49. India Staphylococcal Infection Drugs, by Application USD Million (2014-2019)
  • Table 50. India Staphylococcal Infection Drugs, by Treatment USD Million (2014-2019)
  • Table 51. India Staphylococcal Infection Drugs, by Diagnosis USD Million (2014-2019)
  • Table 52. South Korea Staphylococcal Infection Drugs, by Type USD Million (2014-2019)
  • Table 53. South Korea Staphylococcal Infection Drugs, by Application USD Million (2014-2019)
  • Table 54. South Korea Staphylococcal Infection Drugs, by Treatment USD Million (2014-2019)
  • Table 55. South Korea Staphylococcal Infection Drugs, by Diagnosis USD Million (2014-2019)
  • Table 56. Taiwan Staphylococcal Infection Drugs, by Type USD Million (2014-2019)
  • Table 57. Taiwan Staphylococcal Infection Drugs, by Application USD Million (2014-2019)
  • Table 58. Taiwan Staphylococcal Infection Drugs, by Treatment USD Million (2014-2019)
  • Table 59. Taiwan Staphylococcal Infection Drugs, by Diagnosis USD Million (2014-2019)
  • Table 60. Australia Staphylococcal Infection Drugs, by Type USD Million (2014-2019)
  • Table 61. Australia Staphylococcal Infection Drugs, by Application USD Million (2014-2019)
  • Table 62. Australia Staphylococcal Infection Drugs, by Treatment USD Million (2014-2019)
  • Table 63. Australia Staphylococcal Infection Drugs, by Diagnosis USD Million (2014-2019)
  • Table 64. Rest of Asia-Pacific Staphylococcal Infection Drugs, by Type USD Million (2014-2019)
  • Table 65. Rest of Asia-Pacific Staphylococcal Infection Drugs, by Application USD Million (2014-2019)
  • Table 66. Rest of Asia-Pacific Staphylococcal Infection Drugs, by Treatment USD Million (2014-2019)
  • Table 67. Rest of Asia-Pacific Staphylococcal Infection Drugs, by Diagnosis USD Million (2014-2019)
  • Table 68. Europe Staphylococcal Infection Drugs, by Country USD Million (2014-2019)
  • Table 69. Europe Staphylococcal Infection Drugs, by Type USD Million (2014-2019)
  • Table 70. Europe Staphylococcal Infection Drugs, by Application USD Million (2014-2019)
  • Table 71. Europe Staphylococcal Infection Drugs, by Treatment USD Million (2014-2019)
  • Table 72. Europe Staphylococcal Infection Drugs, by Diagnosis USD Million (2014-2019)
  • Table 73. Germany Staphylococcal Infection Drugs, by Type USD Million (2014-2019)
  • Table 74. Germany Staphylococcal Infection Drugs, by Application USD Million (2014-2019)
  • Table 75. Germany Staphylococcal Infection Drugs, by Treatment USD Million (2014-2019)
  • Table 76. Germany Staphylococcal Infection Drugs, by Diagnosis USD Million (2014-2019)
  • Table 77. France Staphylococcal Infection Drugs, by Type USD Million (2014-2019)
  • Table 78. France Staphylococcal Infection Drugs, by Application USD Million (2014-2019)
  • Table 79. France Staphylococcal Infection Drugs, by Treatment USD Million (2014-2019)
  • Table 80. France Staphylococcal Infection Drugs, by Diagnosis USD Million (2014-2019)
  • Table 81. Italy Staphylococcal Infection Drugs, by Type USD Million (2014-2019)
  • Table 82. Italy Staphylococcal Infection Drugs, by Application USD Million (2014-2019)
  • Table 83. Italy Staphylococcal Infection Drugs, by Treatment USD Million (2014-2019)
  • Table 84. Italy Staphylococcal Infection Drugs, by Diagnosis USD Million (2014-2019)
  • Table 85. United Kingdom Staphylococcal Infection Drugs, by Type USD Million (2014-2019)
  • Table 86. United Kingdom Staphylococcal Infection Drugs, by Application USD Million (2014-2019)
  • Table 87. United Kingdom Staphylococcal Infection Drugs, by Treatment USD Million (2014-2019)
  • Table 88. United Kingdom Staphylococcal Infection Drugs, by Diagnosis USD Million (2014-2019)
  • Table 89. Netherlands Staphylococcal Infection Drugs, by Type USD Million (2014-2019)
  • Table 90. Netherlands Staphylococcal Infection Drugs, by Application USD Million (2014-2019)
  • Table 91. Netherlands Staphylococcal Infection Drugs, by Treatment USD Million (2014-2019)
  • Table 92. Netherlands Staphylococcal Infection Drugs, by Diagnosis USD Million (2014-2019)
  • Table 93. Rest of Europe Staphylococcal Infection Drugs, by Type USD Million (2014-2019)
  • Table 94. Rest of Europe Staphylococcal Infection Drugs, by Application USD Million (2014-2019)
  • Table 95. Rest of Europe Staphylococcal Infection Drugs, by Treatment USD Million (2014-2019)
  • Table 96. Rest of Europe Staphylococcal Infection Drugs, by Diagnosis USD Million (2014-2019)
  • Table 97. MEA Staphylococcal Infection Drugs, by Country USD Million (2014-2019)
  • Table 98. MEA Staphylococcal Infection Drugs, by Type USD Million (2014-2019)
  • Table 99. MEA Staphylococcal Infection Drugs, by Application USD Million (2014-2019)
  • Table 100. MEA Staphylococcal Infection Drugs, by Treatment USD Million (2014-2019)
  • Table 101. MEA Staphylococcal Infection Drugs, by Diagnosis USD Million (2014-2019)
  • Table 102. Middle East Staphylococcal Infection Drugs, by Type USD Million (2014-2019)
  • Table 103. Middle East Staphylococcal Infection Drugs, by Application USD Million (2014-2019)
  • Table 104. Middle East Staphylococcal Infection Drugs, by Treatment USD Million (2014-2019)
  • Table 105. Middle East Staphylococcal Infection Drugs, by Diagnosis USD Million (2014-2019)
  • Table 106. Africa Staphylococcal Infection Drugs, by Type USD Million (2014-2019)
  • Table 107. Africa Staphylococcal Infection Drugs, by Application USD Million (2014-2019)
  • Table 108. Africa Staphylococcal Infection Drugs, by Treatment USD Million (2014-2019)
  • Table 109. Africa Staphylococcal Infection Drugs, by Diagnosis USD Million (2014-2019)
  • Table 110. North America Staphylococcal Infection Drugs, by Country USD Million (2014-2019)
  • Table 111. North America Staphylococcal Infection Drugs, by Type USD Million (2014-2019)
  • Table 112. North America Staphylococcal Infection Drugs, by Application USD Million (2014-2019)
  • Table 113. North America Staphylococcal Infection Drugs, by Treatment USD Million (2014-2019)
  • Table 114. North America Staphylococcal Infection Drugs, by Diagnosis USD Million (2014-2019)
  • Table 115. United States Staphylococcal Infection Drugs, by Type USD Million (2014-2019)
  • Table 116. United States Staphylococcal Infection Drugs, by Application USD Million (2014-2019)
  • Table 117. United States Staphylococcal Infection Drugs, by Treatment USD Million (2014-2019)
  • Table 118. United States Staphylococcal Infection Drugs, by Diagnosis USD Million (2014-2019)
  • Table 119. Canada Staphylococcal Infection Drugs, by Type USD Million (2014-2019)
  • Table 120. Canada Staphylococcal Infection Drugs, by Application USD Million (2014-2019)
  • Table 121. Canada Staphylococcal Infection Drugs, by Treatment USD Million (2014-2019)
  • Table 122. Canada Staphylococcal Infection Drugs, by Diagnosis USD Million (2014-2019)
  • Table 123. Mexico Staphylococcal Infection Drugs, by Type USD Million (2014-2019)
  • Table 124. Mexico Staphylococcal Infection Drugs, by Application USD Million (2014-2019)
  • Table 125. Mexico Staphylococcal Infection Drugs, by Treatment USD Million (2014-2019)
  • Table 126. Mexico Staphylococcal Infection Drugs, by Diagnosis USD Million (2014-2019)
  • Table 127. Staphylococcal Infection Drugs: by Type(USD/Units)
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Staphylococcal Infection Drugs: by Type(USD Million)
  • Table 137. Staphylococcal Infection Drugs Beta-lactams , by Region USD Million (2020-2025)
  • Table 138. Staphylococcal Infection Drugs Peptides , by Region USD Million (2020-2025)
  • Table 139. Staphylococcal Infection Drugs Quinolones , by Region USD Million (2020-2025)
  • Table 140. Staphylococcal Infection Drugs Others , by Region USD Million (2020-2025)
  • Table 141. Staphylococcal Infection Drugs: by Application(USD Million)
  • Table 142. Staphylococcal Infection Drugs Hospital , by Region USD Million (2020-2025)
  • Table 143. Staphylococcal Infection Drugs Pharmacy , by Region USD Million (2020-2025)
  • Table 144. Staphylococcal Infection Drugs Others , by Region USD Million (2020-2025)
  • Table 145. Staphylococcal Infection Drugs: by Treatment(USD Million)
  • Table 146. Staphylococcal Infection Drugs Antibiotics , by Region USD Million (2020-2025)
  • Table 147. Staphylococcal Infection Drugs Wound Drainage , by Region USD Million (2020-2025)
  • Table 148. Staphylococcal Infection Drugs Device Removal , by Region USD Million (2020-2025)
  • Table 149. Staphylococcal Infection Drugs: by Diagnosis(USD Million)
  • Table 150. Staphylococcal Infection Drugs Physical Exam , by Region USD Million (2020-2025)
  • Table 151. Staphylococcal Infection Drugs Tissue Sample or Nasal Secretions , by Region USD Million (2020-2025)
  • Table 152. Staphylococcal Infection Drugs Imaging Test (Echocardiogram) , by Region USD Million (2020-2025)
  • Table 153. South America Staphylococcal Infection Drugs, by Country USD Million (2020-2025)
  • Table 154. South America Staphylococcal Infection Drugs, by Type USD Million (2020-2025)
  • Table 155. South America Staphylococcal Infection Drugs, by Application USD Million (2020-2025)
  • Table 156. South America Staphylococcal Infection Drugs, by Treatment USD Million (2020-2025)
  • Table 157. South America Staphylococcal Infection Drugs, by Diagnosis USD Million (2020-2025)
  • Table 158. Brazil Staphylococcal Infection Drugs, by Type USD Million (2020-2025)
  • Table 159. Brazil Staphylococcal Infection Drugs, by Application USD Million (2020-2025)
  • Table 160. Brazil Staphylococcal Infection Drugs, by Treatment USD Million (2020-2025)
  • Table 161. Brazil Staphylococcal Infection Drugs, by Diagnosis USD Million (2020-2025)
  • Table 162. Argentina Staphylococcal Infection Drugs, by Type USD Million (2020-2025)
  • Table 163. Argentina Staphylococcal Infection Drugs, by Application USD Million (2020-2025)
  • Table 164. Argentina Staphylococcal Infection Drugs, by Treatment USD Million (2020-2025)
  • Table 165. Argentina Staphylococcal Infection Drugs, by Diagnosis USD Million (2020-2025)
  • Table 166. Rest of South America Staphylococcal Infection Drugs, by Type USD Million (2020-2025)
  • Table 167. Rest of South America Staphylococcal Infection Drugs, by Application USD Million (2020-2025)
  • Table 168. Rest of South America Staphylococcal Infection Drugs, by Treatment USD Million (2020-2025)
  • Table 169. Rest of South America Staphylococcal Infection Drugs, by Diagnosis USD Million (2020-2025)
  • Table 170. Asia Pacific Staphylococcal Infection Drugs, by Country USD Million (2020-2025)
  • Table 171. Asia Pacific Staphylococcal Infection Drugs, by Type USD Million (2020-2025)
  • Table 172. Asia Pacific Staphylococcal Infection Drugs, by Application USD Million (2020-2025)
  • Table 173. Asia Pacific Staphylococcal Infection Drugs, by Treatment USD Million (2020-2025)
  • Table 174. Asia Pacific Staphylococcal Infection Drugs, by Diagnosis USD Million (2020-2025)
  • Table 175. China Staphylococcal Infection Drugs, by Type USD Million (2020-2025)
  • Table 176. China Staphylococcal Infection Drugs, by Application USD Million (2020-2025)
  • Table 177. China Staphylococcal Infection Drugs, by Treatment USD Million (2020-2025)
  • Table 178. China Staphylococcal Infection Drugs, by Diagnosis USD Million (2020-2025)
  • Table 179. Japan Staphylococcal Infection Drugs, by Type USD Million (2020-2025)
  • Table 180. Japan Staphylococcal Infection Drugs, by Application USD Million (2020-2025)
  • Table 181. Japan Staphylococcal Infection Drugs, by Treatment USD Million (2020-2025)
  • Table 182. Japan Staphylococcal Infection Drugs, by Diagnosis USD Million (2020-2025)
  • Table 183. India Staphylococcal Infection Drugs, by Type USD Million (2020-2025)
  • Table 184. India Staphylococcal Infection Drugs, by Application USD Million (2020-2025)
  • Table 185. India Staphylococcal Infection Drugs, by Treatment USD Million (2020-2025)
  • Table 186. India Staphylococcal Infection Drugs, by Diagnosis USD Million (2020-2025)
  • Table 187. South Korea Staphylococcal Infection Drugs, by Type USD Million (2020-2025)
  • Table 188. South Korea Staphylococcal Infection Drugs, by Application USD Million (2020-2025)
  • Table 189. South Korea Staphylococcal Infection Drugs, by Treatment USD Million (2020-2025)
  • Table 190. South Korea Staphylococcal Infection Drugs, by Diagnosis USD Million (2020-2025)
  • Table 191. Taiwan Staphylococcal Infection Drugs, by Type USD Million (2020-2025)
  • Table 192. Taiwan Staphylococcal Infection Drugs, by Application USD Million (2020-2025)
  • Table 193. Taiwan Staphylococcal Infection Drugs, by Treatment USD Million (2020-2025)
  • Table 194. Taiwan Staphylococcal Infection Drugs, by Diagnosis USD Million (2020-2025)
  • Table 195. Australia Staphylococcal Infection Drugs, by Type USD Million (2020-2025)
  • Table 196. Australia Staphylococcal Infection Drugs, by Application USD Million (2020-2025)
  • Table 197. Australia Staphylococcal Infection Drugs, by Treatment USD Million (2020-2025)
  • Table 198. Australia Staphylococcal Infection Drugs, by Diagnosis USD Million (2020-2025)
  • Table 199. Rest of Asia-Pacific Staphylococcal Infection Drugs, by Type USD Million (2020-2025)
  • Table 200. Rest of Asia-Pacific Staphylococcal Infection Drugs, by Application USD Million (2020-2025)
  • Table 201. Rest of Asia-Pacific Staphylococcal Infection Drugs, by Treatment USD Million (2020-2025)
  • Table 202. Rest of Asia-Pacific Staphylococcal Infection Drugs, by Diagnosis USD Million (2020-2025)
  • Table 203. Europe Staphylococcal Infection Drugs, by Country USD Million (2020-2025)
  • Table 204. Europe Staphylococcal Infection Drugs, by Type USD Million (2020-2025)
  • Table 205. Europe Staphylococcal Infection Drugs, by Application USD Million (2020-2025)
  • Table 206. Europe Staphylococcal Infection Drugs, by Treatment USD Million (2020-2025)
  • Table 207. Europe Staphylococcal Infection Drugs, by Diagnosis USD Million (2020-2025)
  • Table 208. Germany Staphylococcal Infection Drugs, by Type USD Million (2020-2025)
  • Table 209. Germany Staphylococcal Infection Drugs, by Application USD Million (2020-2025)
  • Table 210. Germany Staphylococcal Infection Drugs, by Treatment USD Million (2020-2025)
  • Table 211. Germany Staphylococcal Infection Drugs, by Diagnosis USD Million (2020-2025)
  • Table 212. France Staphylococcal Infection Drugs, by Type USD Million (2020-2025)
  • Table 213. France Staphylococcal Infection Drugs, by Application USD Million (2020-2025)
  • Table 214. France Staphylococcal Infection Drugs, by Treatment USD Million (2020-2025)
  • Table 215. France Staphylococcal Infection Drugs, by Diagnosis USD Million (2020-2025)
  • Table 216. Italy Staphylococcal Infection Drugs, by Type USD Million (2020-2025)
  • Table 217. Italy Staphylococcal Infection Drugs, by Application USD Million (2020-2025)
  • Table 218. Italy Staphylococcal Infection Drugs, by Treatment USD Million (2020-2025)
  • Table 219. Italy Staphylococcal Infection Drugs, by Diagnosis USD Million (2020-2025)
  • Table 220. United Kingdom Staphylococcal Infection Drugs, by Type USD Million (2020-2025)
  • Table 221. United Kingdom Staphylococcal Infection Drugs, by Application USD Million (2020-2025)
  • Table 222. United Kingdom Staphylococcal Infection Drugs, by Treatment USD Million (2020-2025)
  • Table 223. United Kingdom Staphylococcal Infection Drugs, by Diagnosis USD Million (2020-2025)
  • Table 224. Netherlands Staphylococcal Infection Drugs, by Type USD Million (2020-2025)
  • Table 225. Netherlands Staphylococcal Infection Drugs, by Application USD Million (2020-2025)
  • Table 226. Netherlands Staphylococcal Infection Drugs, by Treatment USD Million (2020-2025)
  • Table 227. Netherlands Staphylococcal Infection Drugs, by Diagnosis USD Million (2020-2025)
  • Table 228. Rest of Europe Staphylococcal Infection Drugs, by Type USD Million (2020-2025)
  • Table 229. Rest of Europe Staphylococcal Infection Drugs, by Application USD Million (2020-2025)
  • Table 230. Rest of Europe Staphylococcal Infection Drugs, by Treatment USD Million (2020-2025)
  • Table 231. Rest of Europe Staphylococcal Infection Drugs, by Diagnosis USD Million (2020-2025)
  • Table 232. MEA Staphylococcal Infection Drugs, by Country USD Million (2020-2025)
  • Table 233. MEA Staphylococcal Infection Drugs, by Type USD Million (2020-2025)
  • Table 234. MEA Staphylococcal Infection Drugs, by Application USD Million (2020-2025)
  • Table 235. MEA Staphylococcal Infection Drugs, by Treatment USD Million (2020-2025)
  • Table 236. MEA Staphylococcal Infection Drugs, by Diagnosis USD Million (2020-2025)
  • Table 237. Middle East Staphylococcal Infection Drugs, by Type USD Million (2020-2025)
  • Table 238. Middle East Staphylococcal Infection Drugs, by Application USD Million (2020-2025)
  • Table 239. Middle East Staphylococcal Infection Drugs, by Treatment USD Million (2020-2025)
  • Table 240. Middle East Staphylococcal Infection Drugs, by Diagnosis USD Million (2020-2025)
  • Table 241. Africa Staphylococcal Infection Drugs, by Type USD Million (2020-2025)
  • Table 242. Africa Staphylococcal Infection Drugs, by Application USD Million (2020-2025)
  • Table 243. Africa Staphylococcal Infection Drugs, by Treatment USD Million (2020-2025)
  • Table 244. Africa Staphylococcal Infection Drugs, by Diagnosis USD Million (2020-2025)
  • Table 245. North America Staphylococcal Infection Drugs, by Country USD Million (2020-2025)
  • Table 246. North America Staphylococcal Infection Drugs, by Type USD Million (2020-2025)
  • Table 247. North America Staphylococcal Infection Drugs, by Application USD Million (2020-2025)
  • Table 248. North America Staphylococcal Infection Drugs, by Treatment USD Million (2020-2025)
  • Table 249. North America Staphylococcal Infection Drugs, by Diagnosis USD Million (2020-2025)
  • Table 250. United States Staphylococcal Infection Drugs, by Type USD Million (2020-2025)
  • Table 251. United States Staphylococcal Infection Drugs, by Application USD Million (2020-2025)
  • Table 252. United States Staphylococcal Infection Drugs, by Treatment USD Million (2020-2025)
  • Table 253. United States Staphylococcal Infection Drugs, by Diagnosis USD Million (2020-2025)
  • Table 254. Canada Staphylococcal Infection Drugs, by Type USD Million (2020-2025)
  • Table 255. Canada Staphylococcal Infection Drugs, by Application USD Million (2020-2025)
  • Table 256. Canada Staphylococcal Infection Drugs, by Treatment USD Million (2020-2025)
  • Table 257. Canada Staphylococcal Infection Drugs, by Diagnosis USD Million (2020-2025)
  • Table 258. Mexico Staphylococcal Infection Drugs, by Type USD Million (2020-2025)
  • Table 259. Mexico Staphylococcal Infection Drugs, by Application USD Million (2020-2025)
  • Table 260. Mexico Staphylococcal Infection Drugs, by Treatment USD Million (2020-2025)
  • Table 261. Mexico Staphylococcal Infection Drugs, by Diagnosis USD Million (2020-2025)
  • Table 262. Staphylococcal Infection Drugs: by Type(USD/Units)
  • Table 263. Research Programs/Design for This Report
  • Table 264. Key Data Information from Secondary Sources
  • Table 265. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Staphylococcal Infection Drugs: by Type USD Million (2014-2019)
  • Figure 5. Global Staphylococcal Infection Drugs: by Application USD Million (2014-2019)
  • Figure 6. Global Staphylococcal Infection Drugs: by Treatment USD Million (2014-2019)
  • Figure 7. Global Staphylococcal Infection Drugs: by Diagnosis USD Million (2014-2019)
  • Figure 8. South America Staphylococcal Infection Drugs Share (%), by Country
  • Figure 9. Asia Pacific Staphylococcal Infection Drugs Share (%), by Country
  • Figure 10. Europe Staphylococcal Infection Drugs Share (%), by Country
  • Figure 11. MEA Staphylococcal Infection Drugs Share (%), by Country
  • Figure 12. North America Staphylococcal Infection Drugs Share (%), by Country
  • Figure 13. Global Staphylococcal Infection Drugs: by Type USD/Units (2014-2019)
  • Figure 14. Global Staphylococcal Infection Drugs share by Players 2019 (%)
  • Figure 15. Global Staphylococcal Infection Drugs share by Players (Top 3) 2019(%)
  • Figure 16. Global Staphylococcal Infection Drugs share by Players (Top 5) 2019(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. The Medicines Company (United States) Revenue, Net Income and Gross profit
  • Figure 19. The Medicines Company (United States) Revenue: by Geography 2019
  • Figure 20. Theravance Biopharma (United States) Revenue, Net Income and Gross profit
  • Figure 21. Theravance Biopharma (United States) Revenue: by Geography 2019
  • Figure 22. Allergan Plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 23. Allergan Plc (Ireland) Revenue: by Geography 2019
  • Figure 24. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 25. Bayer AG (Germany) Revenue: by Geography 2019
  • Figure 26. GlaxoSmithKline Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 27. GlaxoSmithKline Plc (United Kingdom) Revenue: by Geography 2019
  • Figure 28. Merck & Co. Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Merck & Co. Inc. (United States) Revenue: by Geography 2019
  • Figure 30. Pfizer Inc (United States) Revenue, Net Income and Gross profit
  • Figure 31. Pfizer Inc (United States) Revenue: by Geography 2019
  • Figure 32. XBiotech Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. XBiotech Inc. (United States) Revenue: by Geography 2019
  • Figure 34. Global Staphylococcal Infection Drugs: by Type USD Million (2020-2025)
  • Figure 35. Global Staphylococcal Infection Drugs: by Application USD Million (2020-2025)
  • Figure 36. Global Staphylococcal Infection Drugs: by Treatment USD Million (2020-2025)
  • Figure 37. Global Staphylococcal Infection Drugs: by Diagnosis USD Million (2020-2025)
  • Figure 38. South America Staphylococcal Infection Drugs Share (%), by Country
  • Figure 39. Asia Pacific Staphylococcal Infection Drugs Share (%), by Country
  • Figure 40. Europe Staphylococcal Infection Drugs Share (%), by Country
  • Figure 41. MEA Staphylococcal Infection Drugs Share (%), by Country
  • Figure 42. North America Staphylococcal Infection Drugs Share (%), by Country
  • Figure 43. Global Staphylococcal Infection Drugs: by Type USD/Units (2020-2025)
Some of the key companies/manufacturers profiled in the report
  • The Medicines Company (United States)
  • Theravance Biopharma (United States)
  • Allergan Plc (Ireland)
  • Bayer AG (Germany)
  • GlaxoSmithKline Plc (United Kingdom)
  • Merck & Co. Inc. (United States)
  • Pfizer Inc (United States)
  • XBiotech Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation